Stock 300558 BETTA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Betta Pharmaceuticals Co., Ltd.

Equities

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
40.54 CNY +3.66% Intraday chart for Betta Pharmaceuticals Co., Ltd. +12.49% -21.36%
Apr. 19 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 04 C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 26,346 44,361 33,154 20,525 21,573 16,965 - -
Enterprise Value (EV) 1 26,468 43,015 32,367 21,551 23,243 18,940 18,434 18,130
P/E ratio 115 x 72.1 x 86.8 x 141 x 62.1 x 28.3 x 26.7 x 13.4 x
Yield 0.29% 0.29% 0.31% 0.14% 0.33% 0.49% 0.56% 1.53%
Capitalization / Revenue 17 x 23.7 x 14.8 x 8.64 x 8.78 x 4.99 x 3.98 x 3.23 x
EV / Revenue 17 x 23 x 14.4 x 9.07 x 9.46 x 5.57 x 4.32 x 3.45 x
EV / EBITDA 64.6 x 51.4 x 57.3 x 63.1 x 39.7 x 17.8 x 17.7 x 9.91 x
EV / FCF - -1,124 x - - -146 x 20.3 x 11 x 7.99 x
FCF Yield - -0.09% - - -0.69% 4.92% 9.08% 12.5%
Price to Book 10.7 x 10.7 x 7.27 x - 4.11 x 3.07 x 2.86 x -
Nbr of stocks (in thousands) 401,000 413,163 415,305 416,583 418,486 418,486 - -
Reference price 2 65.70 107.4 79.83 49.27 51.55 40.54 40.54 40.54
Announcement Date 2/27/20 3/25/21 4/6/22 4/23/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,554 1,870 2,246 2,377 2,456 3,401 4,265 5,258
EBITDA 1 410 836.5 564.7 341.4 585.4 1,061 1,039 1,830
EBIT 1 266.6 680.7 395.6 94.8 270.1 421.1 346 -
Operating Margin 17.15% 36.39% 17.61% 3.99% 11% 12.38% 8.11% -
Earnings before Tax (EBT) 1 266.5 666.7 389.9 87.57 322.1 682.7 690.6 1,436
Net income 1 230.8 606.4 383.1 145.4 348 599.9 634.1 1,262
Net margin 14.85% 32.42% 17.06% 6.12% 14.17% 17.64% 14.87% 24%
EPS 2 0.5700 1.490 0.9200 0.3500 0.8300 1.430 1.517 3.020
Free Cash Flow 1 - -38.26 - - -159.6 931 1,674 2,270
FCF margin - -2.05% - - -6.5% 27.37% 39.25% 43.17%
FCF Conversion (EBITDA) - - - - - 87.72% 161.14% 124.04%
FCF Conversion (Net income) - - - - - 155.2% 263.99% 179.86%
Dividend per Share 2 0.1900 0.3100 0.2500 0.0700 0.1700 0.1967 0.2250 0.6200
Announcement Date 2/27/20 3/25/21 4/6/22 4/23/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 521.4 584.7 668.6 409.4 713.9 782.3 729.7 412.6 735.8 709.8 921.4 743.4 854.6
EBITDA - - - - - - - - - - - - -
EBIT 12.12 97.04 -21.65 18.6 0.8041 81.58 165.7 - 108.4 - - - -
Operating Margin 2.32% 16.6% -3.24% 4.54% 0.11% 10.43% 22.71% - 14.73% - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - -
Net income - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - -
EPS 2 0.1000 0.2000 0.0300 0.0200 0.1000 0.2300 0.3700 0.1000 0.2300 0.2600 0.3500 0.5900 0.2400
Dividend per Share - - - - - - - - - - - - -
Announcement Date 4/6/22 4/26/22 8/24/22 10/28/22 4/23/23 8/25/23 10/24/23 4/19/24 4/19/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 122 - - 1,026 1,670 1,975 1,469 1,165
Net Cash position 1 - 1,346 787 - - - - -
Leverage (Debt/EBITDA) 0.2984 x - - 3.005 x 2.853 x 1.86 x 1.414 x 0.6364 x
Free Cash Flow 1 - -38.3 - - -160 931 1,674 2,270
ROE (net income / shareholders' equity) 9.84% 21.3% 8.8% - 6.89% 8.68% 9.27% -
ROA (Net income/ Total Assets) 6.08% 13% - - - 5.7% - -
Assets 1 3,796 4,682 - - - 10,524 - -
Book Value Per Share 2 6.140 10.00 11.00 - 12.50 13.20 14.20 -
Cash Flow per Share 2 1.380 1.560 1.260 - 2.180 1.980 0.2100 -
Capex 1 620 684 758 - 1,074 543 335 479
Capex / Sales 39.9% 36.59% 33.76% - 43.72% 15.97% 7.86% 9.11%
Announcement Date 2/27/20 3/25/21 4/6/22 4/23/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Betta Pharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
40.54 CNY
Average target price
54.14 CNY
Spread / Average Target
+33.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300558 Stock
  4. Financials Betta Pharmaceuticals Co., Ltd.